BR112017006005A2 - composição farmacêutica, e, método de prevenção ou tratamento de uma infecção por hiv. - Google Patents

composição farmacêutica, e, método de prevenção ou tratamento de uma infecção por hiv.

Info

Publication number
BR112017006005A2
BR112017006005A2 BR112017006005A BR112017006005A BR112017006005A2 BR 112017006005 A2 BR112017006005 A2 BR 112017006005A2 BR 112017006005 A BR112017006005 A BR 112017006005A BR 112017006005 A BR112017006005 A BR 112017006005A BR 112017006005 A2 BR112017006005 A2 BR 112017006005A2
Authority
BR
Brazil
Prior art keywords
treating
preventing
pharmaceutical composition
hiv infection
hiv
Prior art date
Application number
BR112017006005A
Other languages
English (en)
Inventor
Alvin Johns Brian
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54256799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017006005(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of BR112017006005A2 publication Critical patent/BR112017006005A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

a presente invenção refere-se a composições farmacêuticas de longa atuação ou sais farmaceuticamente aceitáveis do mesmo, úteis no tratamento ou prevenção de infecções por vírus da imunodeficiência humana (hiv).
BR112017006005A 2014-09-26 2015-09-24 composição farmacêutica, e, método de prevenção ou tratamento de uma infecção por hiv. BR112017006005A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462055779P 2014-09-26 2014-09-26
PCT/IB2015/057360 WO2016046786A1 (en) 2014-09-26 2015-09-24 Long acting pharmaceutical compositions

Publications (1)

Publication Number Publication Date
BR112017006005A2 true BR112017006005A2 (pt) 2017-12-19

Family

ID=54256799

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017006005A BR112017006005A2 (pt) 2014-09-26 2015-09-24 composição farmacêutica, e, método de prevenção ou tratamento de uma infecção por hiv.

Country Status (18)

Country Link
US (1) US10092523B2 (pt)
EP (1) EP3197430A1 (pt)
JP (1) JP2017528497A (pt)
KR (1) KR20170056702A (pt)
CN (1) CN106999425A (pt)
AU (1) AU2015323321A1 (pt)
BR (1) BR112017006005A2 (pt)
CA (1) CA2961528A1 (pt)
CL (1) CL2017000714A1 (pt)
CR (1) CR20170113A (pt)
DO (1) DOP2017000086A (pt)
EA (1) EA201790495A1 (pt)
IL (1) IL251337A0 (pt)
MX (1) MX2017003928A (pt)
PE (1) PE20170691A1 (pt)
SG (1) SG11201702379TA (pt)
WO (1) WO2016046786A1 (pt)
ZA (1) ZA201702086B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
WO2014093941A1 (en) 2012-12-14 2014-06-19 Glaxosmithkline Llc Pharmaceutical compositions
KR20170056702A (ko) 2014-09-26 2017-05-23 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 지효성 약제학적 조성물
JP6835841B2 (ja) * 2015-11-16 2021-02-24 エボニック オペレーションズ ゲーエムベーハー 非核酸系逆転写酵素阻害剤とポリ（ラクチド−ｃｏ−グリコリド）とを含む注射液
CN107184551B (zh) * 2017-06-09 2020-09-01 甘肃新天马制药股份有限公司 一种利拉萘酯双粒径分布乳剂及其制备方法
JP7384783B2 (ja) * 2017-07-21 2023-11-21 ヴィーブ ヘルスケア カンパニー Ｈｉｖ感染症及びａｉｄｓを治療するためのレジメン
CA3164528A1 (en) * 2019-12-09 2021-06-17 Viiv Healthcare Company Pharmaceutical compositions comprising cabotegravir
CN115844838B (zh) * 2022-12-01 2023-10-24 浙江萃泽医药科技有限公司 一种可注射的药物组合物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5358721A (en) 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
WO2001090046A1 (en) 2000-05-23 2001-11-29 Univerzita Palackeho V Olomouci Triterpenoid derivatives
DE10103810A1 (de) 2001-01-29 2002-08-01 Map Gmbh Vorrichtung zur Zufuhr eines Atemgases
US7163700B2 (en) 2001-07-31 2007-01-16 Capricorn Pharma, Inc. Amorphous drug beads
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US20080206161A1 (en) 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
US20050142205A1 (en) 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
US20060019934A1 (en) 2004-05-20 2006-01-26 Saxena Brij B Anti-HIV-1 activity of betulinol derivatives
US7150323B2 (en) 2004-07-26 2006-12-19 Vetco Gray Inc. Shoulder ring set on casing hanger trip
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
US20090023698A1 (en) 2005-03-29 2009-01-22 Krasutsky Pavel A Methods of manufacturing bioactive 3-esters of betulinic aldehyde and betulinic acid
TW201414495A (zh) * 2005-04-04 2014-04-16 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
WO2006117666A2 (en) 2005-04-29 2006-11-09 Pfizer Inc. Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery
EP1986654A2 (en) 2006-02-21 2008-11-05 Achillion Pharmaceuticals, Inc. Substituted taraxastanes useful for treating viral infections
FI121468B (fi) 2006-06-07 2010-11-30 Valtion Teknillinen Betuliiniperäiset yhdisteet antimikrobisina aineina
BR122020011487B1 (pt) 2006-06-23 2024-02-20 Janssen Sciences Ireland Uc Composição farmacêutica compreendendo micro ou nanopartículas do composto tmc278 e seu processo de preparação
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
CA2668452A1 (en) 2006-11-03 2008-05-15 Panacos Pharmaceuticals, Inc. Extended triterpene derivatives
JP2011508748A (ja) 2008-01-03 2011-03-17 バイロケム ファーマ インコーポレイテッド 新規のルパン誘導体
WO2009082818A1 (en) 2008-01-03 2009-07-09 Virochem Pharma Inc. Novel c-21-keto lupane derivatives preparation and use thereof
DE102008037025C5 (de) 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
WO2010053817A1 (en) 2008-11-04 2010-05-14 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
CZ2008723A3 (cs) 2008-11-13 2010-01-13 Univerzita Palackého v Olomouci 2-Deoxyglykosidy triterpenoidu, zpusob jejich prípravy a jejich použití jako lécivo
AU2009325128B2 (en) 2008-12-11 2015-01-29 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
US8802727B2 (en) 2009-07-14 2014-08-12 Hetero Research Foundation, Hetero Drugs Limited Pharmaceutically acceptable salts of betulinic acid derivatives
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
US20110051713A1 (en) 2009-08-27 2011-03-03 Xerox Corporation Facsimile prioritization within internet protocol call networks
SG182769A1 (en) * 2010-02-11 2012-09-27 Glaxosmithkline Llc Derivatives of betulin
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
WO2013020246A1 (en) 2011-08-08 2013-02-14 Glaxosmithkline Llc Methylene derivatives of betulin
WO2013020245A1 (en) 2011-08-08 2013-02-14 Glaxosmithkline Llc Carbonyl derivatives of betulin
IN2014CN04449A (pt) 2011-12-14 2015-09-04 Glaxosmithkline Llc
CN104844679B (zh) 2011-12-16 2017-03-01 葛兰素史克有限责任公司 白桦脂醇的衍生物
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
US20150209273A1 (en) 2012-08-28 2015-07-30 Glaxosmithkline Llc Pharmaceutical Compositions
WO2014093941A1 (en) 2012-12-14 2014-06-19 Glaxosmithkline Llc Pharmaceutical compositions
KR20170056702A (ko) 2014-09-26 2017-05-23 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 지효성 약제학적 조성물

Also Published As

Publication number Publication date
CN106999425A (zh) 2017-08-01
US10092523B2 (en) 2018-10-09
KR20170056702A (ko) 2017-05-23
WO2016046786A1 (en) 2016-03-31
SG11201702379TA (en) 2017-04-27
IL251337A0 (en) 2017-05-29
DOP2017000086A (es) 2017-06-30
CL2017000714A1 (es) 2017-11-03
PE20170691A1 (es) 2017-06-13
US20170246118A1 (en) 2017-08-31
JP2017528497A (ja) 2017-09-28
AU2015323321A1 (en) 2017-04-13
ZA201702086B (en) 2019-06-26
EA201790495A1 (ru) 2017-09-29
MX2017003928A (es) 2017-06-28
EP3197430A1 (en) 2017-08-02
CA2961528A1 (en) 2016-03-31
CR20170113A (es) 2017-05-26

Similar Documents

Publication Publication Date Title
BR112017006005A2 (pt) composição farmacêutica, e, método de prevenção ou tratamento de uma infecção por hiv.
BR112015013695A2 (pt) composição farmacêutica, e, métodos para tratamento e para prevenção de uma infecção por hiv
MX2017008720A (es) Derivados y metodos para tratamiento de las infecciones por hepatitis b.
BR112017022544A2 (pt) ?composto, composição, e, método para tratamento de infecção por hiv?.
CY1122792T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου
EA201792069A1 (ru) Производные азокана и азонана и способы лечения инфекций гепатита в
CU20150096A7 (es) Compuestos de amida y composición farmacéutica para el tratamiento de vih
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
BR112018005904A2 (pt) composto, e, método de prevenção e/ou tratamento do hiv.
BR112018005870A2 (pt) composto, e, método de prevenção e/ou tratamento do hiv.
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
MX2018000092A (es) Nuevo lipolantipeptido biciclico, preparacion y uso como agente antimicrobiano.
PH12017500816A1 (en) Long acting pharmaceutical compositions for hepatitis c
CL2017001160A1 (es) Combinación de composiciones de acción prolongada y métodos para la hepatitis c
MX2018011095A (es) Compuestos de carbapenem.
BR112018003181A2 (pt) composto, composição, e, método para tratar infecção por hiv
BR112018002678A2 (pt) composto, composição, e, método para tratar infecção por hiv
BR112016029619A2 (pt) novas fluoroquinolonas e sesu usos no tratamento de infecções bacterianas
PH12017501943B1 (en) Influenza virus neutralizing peptidomimetic compounds
BR112017027082A2 (pt) composição farmacêutica, método para tratar infecção, extrato, método para reduzir a carga viral
BR112017022796A2 (pt) composições antibacterianas e métodos
BR112018002681A2 (pt) ?composto, composição, e, método para tratamento de infecção por hiv?
WO2016094518A3 (en) Novel cyclic peptides and methods using same
WO2015120127A3 (en) Treating flavivirus infections with amodiaquine and derivatives thereof

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]